Approval · Notice of Compliance 29469 · 2022
DARZALEX: Notice of Compliance 29469
Issued November 15, 2022
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 29469
- Date
- November 15, 2022
- Company
- Janssen Inc.Toronto, Ontario, Canada
- Product type
- Biologic
- Submission
- Supplement to a New Drug Submission (SNDS), supplement
- Submission class
- Other
- Reason
- Product Monograph Update
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| DARZALEX | Not yet assigned | — |
| DARZALEX SC | Not yet assigned | — |
Medicinal ingredients
- DARATUMUMAB 100 MG per 5ML
- DARATUMUMAB 400 MG per 20ML
- DARATUMUMAB 1,800 MG per 15ML